Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Cortot

Showing results (221-230 of 224) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 224 results.
Nature|June 1, 2001
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's diseaseJ P Hugot, M Chamaillard, H Zouali, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2019
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trialD Moro-Sibilot, N Cozic, M Pérol, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 14, 2026
Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trialG Zalcman, A Madroszyk, E Guenzi, et al.
The American Journal of Gastroenterology|August 16, 2017
Dramatic Increase in Incidence of Ulcerative Colitis and Crohn's Disease (1988-2011): A Population-Based Study of French AdolescentsSilvia Ghione, Hélène Sarter, Mathurin Fumery, et al.
Pageof 23

Showing results (221-230 of 224) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 224 results.
Nature|June 1, 2001
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's diseaseJ P Hugot, M Chamaillard, H Zouali, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2019
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trialD Moro-Sibilot, N Cozic, M Pérol, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 14, 2026
Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trialG Zalcman, A Madroszyk, E Guenzi, et al.
The American Journal of Gastroenterology|August 16, 2017
Dramatic Increase in Incidence of Ulcerative Colitis and Crohn's Disease (1988-2011): A Population-Based Study of French AdolescentsSilvia Ghione, Hélène Sarter, Mathurin Fumery, et al.
Pageof 23